Eyelid Skin Cancers
The eyelids are among the most common sites for skin cancer on the face. Early detection, precise surgical excision, and expert eyelid reconstruction preserve both function and appearance.
⚠ Warning Signs: Any new growth, non-healing sore, loss of eyelashes in a localized area, or a lesion that bleeds, crusts, or changes in size on or near the eyelid should be evaluated promptly. Eyelid skin cancers are highly treatable when caught early.
Eyelid Skin Cancer Types
Basal Cell Carcinoma
The most common eyelid malignancy. Grows slowly, rarely metastasizes, but can invade the orbit if left untreated. Appears as a pearly nodule or ulcerated lesion, often on the lower eyelid.
Squamous Cell Carcinoma
More aggressive than basal cell, with potential for regional spread. May appear as a rough, scaly, red plaque or an open sore. UV exposure is a primary risk factor.
Sebaceous Gland Carcinoma
Often misdiagnosed as a chalazion or blepharitis. One of the most aggressive eyelid malignancies — requires expert oculoplastic evaluation when lid inflammations recur repeatedly.
Excision & Reconstruction
Step 1: Biopsy & Pathology
A small tissue sample confirms the cancer type and guides the surgical approach. Frozen section pathology may be used during surgery to confirm clear margins in real time.
Step 2: Mohs Micrographic Surgery
For most eyelid skin cancers, we coordinate with a Mohs surgeon to remove all cancer cells with the smallest possible margin of normal tissue.
Step 3: Eyelid Reconstruction
Dr. Shepler reconstructs the eyelid after cancer removal — restoring normal function, tear drainage, corneal protection, and appearance with advanced oculoplastic techniques.
Step 4: Follow-Up Monitoring
Regular surveillance exams monitor for recurrence. Most patients require check-ups at 6 and 12 months, then annually for 5 years.
Have a Suspicious Eyelid Lesion Evaluated
Any persistent growth, sore, or lash loss on the eyelid deserves prompt expert evaluation. Dr. Shepler has extensive experience distinguishing benign lesions from malignant ones and providing definitive treatment.